Alexander Kokkinos Carel Le Roux To view or add a comment, sign in Tirzepatide: Redefining Outcomes in Diabetes & Obesity Care Clinical trials show tirzepatide, a dual GIP/GLP-1 receptor agonist, is delivering results beyond expectations: Up to 20.9% mean weight loss at 72 weeks (SURMOUNT-1, NEJM) 94% risk reduction in progression from prediabetes to type 2 diabetes over 3 years Superior HbA1c reduction and weight control vs leading GLP-1 therapies (SURPASS program) With manageable side effects and durable outcomes, tirzepatide is reshaping how we approach metabolic disease
Many Americans May Need More Potassium White Plains, New York, November 15, 2016 During a recent analysis of potassium supplements sold in the U.S
Peptides can also support weight management, muscle growth, faster recovery, improved sleep, and higher energy levels
After cleansing, take a pad and gently sweep across the face, avoiding the eye area